EE87 Economic Evauation of Adalimumab Biosimilars and JAK Inhibitors for the Treatment of Moderate-to-Severe Rheumatoid Arthritis

To determine the cost effectiveness of adalimumab biosimilars, an anti TNF biologic and current licensed Janus kinase (JAK) inhibitors for the treatment of moderate-to-severe Rheumatoid Arthritis (RA). METHOD A treatment sequence age-dependent Markov model was developed to compare the cost effectiveness of adalimumab biosimilars versus JAK inhibitors (upadacitinib, filgotinib, tofacitinib and baricitinib). Model outcomes were based on 10,000 simulations with ACR20, ACR50 and ACR70 probabilities determined from SELECT COMPARE, FINCH 1, ORAL STANDARD, RA-BEAM and RA-BUILD studies.